Fig 1: High-level E-selectin expression by E-sel/AAV2/2 treatment in ischemic limb tissues. (A) Endogenous E-sel mRNA measured by RT-qPCR is transiently upregulated in untreated ischemic muscle normalized to untreated non-ischemic muscle. (B) Relative E-sel mRNA in E-sel/AAV2/2-treated ischemic muscle normalized to LacZ/AAV2/2-treated ischemic muscle (red) demonstrates high-level E-sel expression compared to endogenous levels in untreated ischemic muscle (black). (C) E-sel mRNA levels are stable from 1 to 3 weeks after treatment with E-sel/AAV2/2. (D) Comparison of E-sel mRNA expression by AAV2/2 and AAV2/9 vectors demonstrating no significant difference on POD 7. (E) Quantification and (F) representative images of immunofluorescence staining for CD31 (red) and E-selectin (green) showing enhanced colocalization (yellow) of these markers in muscle treated with E-sel/AAV2/2 (pointed arrowheads) compared to CD31 staining in absence of E-selectin positivity in muscle treated with LacZ/AAV2/2 (diamond arrowheads). Scale bars represent 50 μm. Data are presented as mean ± SEM where *P < 0.05, **P < 0.01, ***P < 0.001, and ns, not significant (P > 0.05).